Related by context. All words. (Click for frequent words.) 72 depressive symptom 71 HAM D# 71 YMRS 71 Montgomery Asberg Depression 71 PANSS 70 HRQOL 70 HRQoL 70 Montgomery Åsberg Depression 69 HRQL 69 QoL 69 HAMD 69 Rating Scale MADRS 68 subscales 68 RLS symptoms 68 psychosocial functioning 68 UPDRS 68 NIH CPSI 68 nasal symptom 68 subscale scores 68 MADRS score 68 depressive symptoms 68 HDRS 68 ADCS CGIC 68 BMI z 67 Negative Syndrome 67 MADRS 67 ADAS cog 67 Global Impression CGI 67 MMSE score 67 WOMAC pain 67 Global Impression 67 Neuropsychiatric Inventory NPI 66 Depressive symptoms 66 Scale PANSS 66 Crohn Disease Activity 66 Unified Parkinson Disease 66 non menstrual pelvic 66 depressive symptomatology 66 Brief Psychiatric 66 somatic symptoms 66 EQ 5D 66 ADHD RS 66 Health Assessment Questionnaire 66 extrapyramidal symptoms 65 IBDQ 65 SGRQ 65 Alzheimer Disease Assessment 65 point Likert scale 65 psychiatric comorbidity 65 symptomatology 65 Inventory BPI 65 MMSE scores 65 cognitive affective 65 Index CDAI 65 DAS# [002] 65 Visual Analogue Scale VAS 64 symptom checklist 64 daytime somnolence 64 Score DAS# 64 PANSS total 64 abdominal pain abdominal discomfort 64 dyspnea 64 Visual Analog Scale 64 subscores 64 psychopathological symptoms 64 subsyndromal 64 International Prostate Symptom 64 comorbid depression 64 NIHSS 64 HADS 63 ADHD symptoms 63 Symptom severity 63 salivary cortisol 63 ADAS Cog 63 emotional lability 63 urinary symptoms 63 daytime alertness 63 Pain Intensity 63 subscore 63 Distress Scale 63 somatic complaints 63 premorbid 63 nonpsychotic 63 rhinoconjunctivitis 63 comorbid 63 neurocognitive function 63 hypersomnia 63 Hamilton Rating Scale 63 BPRS 63 Psoriasis Area 63 Brief Pain 63 Y BOCS 62 affective psychosis 62 neurocognitive functioning 62 CDAI 62 HAQ DI 62 Disease Activity 62 Expanded Disability Status 62 euthymic patients 62 SELENA SLEDAI 62 citalopram 62 erection hardness 62 TNSS 62 desvenlafaxine succinate 62 hyperarousal 62 Rating Scale UPDRS 62 psychosocial variables 62 nasal obstruction 62 pramipexole 62 comorbidity 62 Scale cognitive subscale 62 Rating Scale BPRS 62 CDAI score 62 dyspnoea 62 UPDRS motor 62 poststroke 62 Scale EDSS 62 overactive bladder symptoms 62 HAM D 62 CONCERTA ® 62 incontinence episodes 62 WOMAC 62 CPAP adherence 62 MMSE 62 Score DAS 62 solifenacin 61 affective disorders 61 Endothelial function 61 GERD symptoms 61 apnea hypopnea index 61 Fibromyalgia Impact Questionnaire 61 CI -#.# 61 alexithymia 61 akathisia 61 comorbid anxiety 61 affective psychoses 61 Score IPSS 61 QIDS SR 61 Suicidal ideation 61 posttreatment 61 akinesia 61 concomitant medications 61 hypopneas 61 IBS symptoms 61 HbA 1c levels 61 HbA1c levels 61 psychiatric morbidity 61 schizophrenia schizoaffective disorder 61 PANSS scores 61 achieved statistical significance 61 autonomic dysfunction 61 covariate 61 serum BDNF 61 albuminuria 61 hypochondriasis 61 syndromal 61 Depression Inventory 61 serum cortisol 61 reflux symptoms 61 vasomotor 61 #mg/day [001] 61 nondepressed 61 euthymic 61 EDSS score 61 p = .# [002] 61 hematologic parameters 61 venlafaxine XR 61 antipsychotic efficacy 61 convergent validity 61 psychiatric comorbidities 61 Physical Component 61 corticosteroid dose 61 chronicity 61 Epworth Sleepiness Scale 61 Mania Rating Scale 61 IRLS score 61 oxcarbazepine 61 hyperalgesia 61 clinically meaningful improvements 61 TEAEs 60 clinically meaningful improvement 60 meta regression 60 Knodell necroinflammatory score 60 Rating Scale 60 cardiac autonomic 60 IPSS 60 oxycodone CR 60 adrenal function 60 Secondary endpoints 60 aminotransferases 60 bothersome symptom 60 serum urate 60 Visual Analog 60 neuropsychological functioning 60 MoxDuo TM IR 60 elevated ALT 60 interrater reliability 60 nighttime awakenings 60 carotid IMT 60 Glasgow Coma Scale 60 IIEF 60 P = .# 60 preoperatively 60 EORTC QLQ C# 60 PSQI 60 alanine aminotransferase ALT 60 neuropsychiatric symptoms 60 placebo p = 60 adjunctive placebo 60 tic severity 60 NIHSS score 60 clomipramine 60 plasma cortisol 60 dysthymia 60 logistic regression model 60 clinically meaningful reductions 60 daytime sleepiness 60 postop 60 analgesic medications 60 salivary flow 60 Depression Rating Scale 60 #q# deletion syndrome 60 spontaneous bowel movements 60 EDSS scores 60 retinal thickness 60 ADHD Rating Scale 60 parkinsonism 60 virological response 60 NYHA functional class 60 urinary N telopeptide 60 nausea photophobia 60 adenotonsillectomy 60 intima media thickness 60 metabolic parameters 59 serum concentrations 59 Functional Assessment 59 untreated psychosis 59 SSRI SNRI 59 attain statistical significance 59 Primary endpoints 59 subthreshold depression 59 comorbid disorders 59 Symptom Checklist 59 ADCS ADL 59 liver histology 59 neuroleptics 59 fasting insulin 59 Neuropsychiatric Inventory 59 PHQ 9 59 DLQI 59 SGPT 59 mRS 59 prodromal symptoms 59 psychophysiological 59 HbA 1c 59 paresthesias 59 hypoglycemic events 59 CORE OM 59 postintervention 59 systemic corticosteroid 59 quetiapine XR 59 depression irritability 59 Severity Index PASI 59 Scale Cognitive Subscale 59 tranylcypromine 59 PLMS 59 decrements 59 hypomanic symptoms 59 Pain Rating Scale 59 LUTS 59 rCBF 59 State Examination MMSE 59 tolterodine ER 59 serologically active patients 59 pentoxifylline 59 adjunctive ABILIFY 59 OSAHS 59 CFQ R 59 comorbid conditions 59 CNS LS 59 constipation nausea 59 alanine aminotransferase 59 generalized anxiety disorder GAD 59 SCr 59 SRBD 59 Severity MSCS score 59 racemic albuterol 59 aminotransferase levels 59 prolactin levels 59 mood lability 59 GERD symptom 59 albumin excretion 59 placebo p 59 INVEGA ® 59 Clinician Administered PTSD 59 exploratory endpoints 59 erythrocyte sedimentation rate 59 serum IGF 59 serum testosterone 58 Ocular Surface Disease 58 antidepressant efficacy 58 DAS# CRP 58 rotigotine 58 symptom exacerbation 58 parkinsonian 58 hemoglobin A1c levels 58 posttransplant 58 T2DM 58 non aspirin NSAIDs 58 fasting plasma glucose 58 nausea constipation 58 nonfatal MI 58 Comorbidity 58 Incontinence Impact Questionnaire 58 blood Phe levels 58 Scale EDSS score 58 bronchial hyperresponsiveness 58 EDSS 58 systolic BP 58 epigastric pain 58 dactylitis 58 pyridostigmine 58 idiopathic Parkinson disease 58 oxygen desaturation 58 inflammatory biomarkers 58 non affective psychosis 58 albumin excretion rate 58 BILAG 58 Secondary efficacy endpoints 58 tic disorder 58 unipolar depression 58 SGAs 58 episodic migraine 58 APACHE II 58 postprocedure 58 PASI scores 58 moderate renal impairment 58 fluoxetine Prozac 58 postoperative complication 58 Index CDAI score 58 asthma exacerbation 58 levodopa therapy 58 serum estradiol 58 interobserver 58 timepoints 58 IRLS 58 generalized epilepsy 58 eszopiclone 58 symptomatic VTE 58 overnight polysomnography 58 serum urate levels 58 elevated creatinine 58 antihypertensive therapy 58 comorbidities 58 tertiles 58 DAS# scores 58 hippocampal volumes 58 Preoperatively 58 laboratory abnormalities 58 Geriatric Depression 58 interpersonal psychotherapy 58 AGILECT ® 58 colorectal adenoma 58 vasomotor symptoms 58 tapentadol ER 58 left ventricular diastolic 58 insulin detemir 58 constipation predominant IBS 58 sensory gating 58 Abnormal Involuntary Movement 58 Likert pain 58 OAB symptoms 58 HbA 1C 58 sociodemographic characteristics 58 esomeprazole 58 comorbid psychiatric 58 internalizing behaviors 58 analgesic efficacy 58 neuroleptic 58 platelet reactivity 58 radiographic progression 58 function subscale 58 Secondary endpoints included 58 endometrial thickness 58 Nocturia 58 left ventricular systolic 57 arterial oxygen saturation 57 urodynamic parameters 57 etanercept 57 hippocampal volume 57 coronary stenosis 57 lipid parameters 57 somatoform disorders 57 locomotor activity 57 lipid profiles 57 nasal airflow 57 apnea hypopnea 57 PSADT 57 daytime drowsiness 57 cortisol secretion 57 subclinical atherosclerosis 57 subjective sleepiness 57 mcg QD 57 ropivacaine 57 serum bicarbonate 57 metabolite concentrations 57 posttest 57 NPH insulin 57 ziprasidone 57 ACR Pedi 57 psychometric properties 57 divalproex sodium 57 rhinorrhea 57 nasal symptoms 57 subthreshold 57 serum uric acid 57 dyskinesia 57 tolvaptan 57 serum sodium 57 postural sway 57 manic hypomanic 57 hyperreflexia 57 enthesitis 57 risperidone Risperdal 57 hepatic enzyme 57 primidone 57 glomerular filtration 57 hyperactivity impulsivity 57 tic disorders 57 thyrotropin levels 57 coronary calcification 57 cognitive domains 57 multivariate analyzes 57 Likert scale 57 Visual acuity 57 actigraphy 57 glycosylated hemoglobin levels 57 AGILECT R 57 glycosylated hemoglobin HbA1c 57 Sociodemographic 57 aldosterone antagonist 57 postoperative AF 57 virologic response 57 bulimia nervosa 57 quetiapine 57 interobserver reliability 57 QTc intervals 57 UPDRS scores 57 QTc interval 57 cognitive functioning 57 detrusor 57 psychotic symptoms 57 inattention hyperactivity 57 NNT = 57 tipranavir r 57 diastolic pressures 57 nocturnal hypoglycemia 57 aspartate aminotransferase 57 systolic function 57 mTSS 57 psychomotor 57 MSLT 57 p = #.# [002] 57 β blocker 57 F FDG PET 57 QTc 57 Irritability 57 Cronbach alpha 57 HOMA IR 57 Beck Anxiety Inventory 57 mg BID dose 57 orthostatic hypotension 57 methotrexate monotherapy 57 aspartate aminotransferase AST 57 attention-deficit/hyperactivity disorder ADHD 57 prodrome 57 fasting glucose levels 57 Depression Inventory BDI 57 serum PSA 57 bivariate analyzes 57 ETDRS 57 nocturnal awakenings 57 MADRS scores 57 WOMAC scores 57 HPA axis 57 postoperative mortality 57 4mg/kg 57 urinary oxalate 57 postinjury 57 CIBIC + 57 schizophreniform disorder 57 sociodemographic factors 57 clinically meaningful 57 tryptophan depletion 57 Postoperatively 57 suicidal ideation 57 detrusor overactivity 57 GH deficiency 57 electroencephalographic 57 serum retinol 57 creatinine clearance 57 univariate analyzes 57 fasting plasma glucose FPG 57 cerebral oxygenation 57 RLAI 57 somatic symptom 57 mania hypomania 57 serum potassium 57 Likert type 56 pregabalin 56 #mg/day [002] 56 myoclonus 56 aspirin NSAIDs 56 nocturnal enuresis 56 infarct size 56 Mean Symptom Complex 56 frequent awakenings 56 Secondary endpoints include 56 PMS symptoms 56 ictal 56 plasma glucose concentration 56 subsyndromal depression 56 plasma triglycerides 56 neurologic dysfunction 56 premenopause 56 somatoform disorder 56 neurodevelopmental impairment 56 Fasting plasma glucose 56 cognitive function 56 pruritis 56 logistic regression analyzes 56 nocturia 56 pharmacologic treatments 56 Cognitive behavioral 56 aripiprazole 56 hypomanic episodes 56 placebo 56 primary aldosteronism 56 acetabular dysplasia 56 HbA1C levels 56 hip BMD 56 x ULN 56 atrioventricular block 56 neurocognitive 56 Major Depressive Disorder 56 postprandial glucose 56 perceptual reasoning 56 inflammatory markers 56 Status Scale EDSS 56 hours postdose 56 nonobese 56 prespecified secondary 56 Negative Symptoms 56 carotid stenosis 56 anticonvulsant medications 56 asthma exacerbations 56 plasma creatinine 56 cerebral perfusion 56 secondary efficacy endpoint 56 somnolence sleepiness 56 psychopathology 56 urate lowering therapy 56 glycated hemoglobin levels 56 airway responsiveness 56 allostatic load 56 menopausal symptom 56 pain subscale 56 multivariable analysis 56 Seattle Angina Questionnaire 56 haloperidol 56 Rating Scale IRLS 56 rheumatoid factor 56 serum folate concentrations 56 metabolic syndrome MetS 56 Apgar scores 56 intraobserver 56 % CI #.#-#.# [004] 56 fluticasone salmeterol 56 AST ALT 56 phonophobia 56 serum PTH 56 plasma glucose 56 cranial irradiation 56 erectile function 56 baseline HbA1c 56 sociodemographic variables 56 df = 56 aPTT 56 abdominal adiposity 56 Edinburgh Postnatal Depression 56 tegaserod 56 carotid intima media 56 methacholine challenge 56 Dyspnea 56 transaminases 56 QOL 56 transaminase elevations 56 adalimumab 56 mL/min/#.# m 2 56 lamotrigine 56 plasma leptin 56 postoperatively 56 sputum eosinophils 56 SSRI citalopram 56 PERMP 56 tiotropium 56 quetiapine Seroquel 56 dysuria 56 lacosamide 56 Likert 56 WOMAC TM 56 orthostatic 56 gastrointestinal motility 56 hypomagnesemia 56 p = .# [001] 56 dopaminergic therapy 56 electrophysiologic 56 Mini Mental 56 fractional anisotropy 56 biochemical recurrence 56 BPH LUTS 56 urolithiasis 56 logistic regression analysis 56 schizotypal traits 56 HER2 expression 56 mucosal inflammation 56 atypical antipsychotic medications 56 radicular pain 56 imipramine 56 serum cholesterol 56 timepoint 56 leukocyte counts 56 POAG 56 BoNTA 56 plasma folate 56 Sleep disturbances 56 intestinal motility 56 Female Sexual Function 56 suicide attempters 56 hsCRP levels 56 PCWP 56 semiquantitative 56 antiepileptics 56 β blockers 56 Index FSFI 56 coronary artery calcification 56 dyspareunia 56 hyperactivity inattention 56 subclinical hypothyroidism 56 hydroxyvitamin D levels 56 Symptom 56 creatinine ratio 56 serum HBV DNA 56 dose Iluvien 56 divalproex 56 somatization 56 peak expiratory flow 56 psychoeducation 56 paricalcitol 56 secondary endpoint 56 inotropic agents 56 oral antidiabetes drugs 56 acromegalic patients 56 Logistic regression 56 cortical activation 56 1mg dose 56 parkinsonian symptoms 56 allodynia 56 mood swings irritability 56 flow mediated dilation 56 acamprosate 56 elevated IOP 55 sulfasalazine 55 Outcomes Study 55 QTc prolongation 55 antihypertensive medications 55 mg TID 55 lowest tertile 55 neuropsychological 55 Child Behavior Checklist 55 meta analytic 55 NIS LL 55 neuropathic 55 intima media thickness IMT 55 exhaled nitric oxide 55 diarrhea flatulence 55 d dimer 55 â ‰ ¥ 55 neurodevelopmental outcome 55 MetS 55 Mental Component 55 psychodynamic psychotherapy 55 urate levels 55 macroalbuminuria 55 pulmonary capillary wedge 55 esophageal motility 55 variance ANOVA 55 hypoglycemic episodes 55 sertraline 55 predictive validity 55 #mg doses [002] 55 fluoxetine 55 cholinergic tone 55 gastro esophageal reflux 55 ventricular tachyarrhythmia 55 generalized seizures 55 mg QD 55 generalized anxiety disorder 55 adenoma recurrence 55 Logistic regression analysis 55 neurologic symptoms 55 ANOVA 55 sd = 55 baseline A1C 55 extrapyramidal side 55 QT intervals 55 nicardipine 55 montelukast 55 serum aminotransferase levels 55 major depressive disorder 55 EFFEXOR XR 55 confidence intervals CIs 55 annualized relapse 55 Postoperative 55 Subgroup analyzes 55 lipid lowering agents 55 Descriptive statistics 55 suicidality 55 bipolar depression 55 neurocognitive impairment 55 BPH symptom 55 white matter hyperintensities 55 dysmenorrhea 55 serum phosphate 55 posttraumatic 55 covariates 55 antidiabetic medications 55 haematologic 55 arousals 55 ANCOVA 55 conditional logistic regression 55 Generalized Anxiety Disorder 55 retest reliability 55 opioid induced 55 PsA 55 acoustic startle 55 Mood disorders 55 Hb A1C 55 hemodynamic parameters 55 demonstrated statistically significant 55 Ashworth Scale 55 hsCRP 55 COPD exacerbation 55 Multiple linear regression 55 H2RAs 55 AUA Symptom Score 55 6MWD 55 attention-deficit/hyperactivity disorder 55 nonsignificant 55 Pred Forte 55 mRNA expression 55 dysarthria 55 urinary albumin 55 plain radiographs 55 concomitant AEDs 55 PSA kinetics 55 dyslipidaemia 55 FACIT 55 knee osteoarthritis OA 55 Main Outcome Measures 55 gout flares 55 nasal polyposis 55 amisulpride 55 atherogenic dyslipidemia 55 neurocognition 55 vitreous haze 55 hepatic lesions 55 hypercholesterolaemia 55 diabetes mellitus DM 55 fasting plasma 55 conjunctival hyperemia 55 abnormal ejaculation 55 thromboembolic 55 DSM IV criteria 55 inflammatory lesions 55 GI motility 55 CSBMs 55 Score TOS 55 serum clusterin levels 55 intact parathyroid hormone 55 sleep disturbances 55 neutropaenia 55 diplopia 55 hepatic function 55 plasma pharmacokinetics 55 confidence interval CI 55 HIV HCV coinfected 55 dichotomized 55 estimated glomerular filtration 55 diarrhea predominant IBS 55 plus methotrexate 55 myocardial reperfusion 55 BYSTOLIC 55 antidepressant therapy 55 % Confidence Interval 55 p = #.# [003] 55 LVEF 55 antimuscarinic 55 8mg/kg 55 tissue oxygenation 55 ejaculatory control 55 elevated serum creatinine 55 CLBP 55 serotonin reuptake inhibitors 55 psychotic disorders 55 #OHD 55 migraineurs 55 baseline PASI 55 Numeric Rating Scale 55 dizziness nausea diarrhea 55 potential confounding variables 55 platelet activation 55 Visual Analogue Scale 55 risperidone 55 urinary excretion 55 generalized tonic clonic seizures 55 EXJADE 55 impaired cognition 55 somnolence dizziness 55 apneas 55 p = #.# [004] 55 virologic breakthrough 55 FEV1 55 CLA supplementation 55 serum creatinine levels 55 dose proportionality 55 hyposmia 55 HRCT 55 IOP lowering 55 ATACAND 55 gastro oesophageal reflux 55 NAbs 55 corticosteroid therapy 55 dissociative symptoms 55 tibiofemoral 55 intraocular pressure IOP 55 inotropes 55 subclinical cardiovascular disease 55 postdose 55 triacylglycerol concentrations 55 guanfacine extended release 55 severe exacerbations 55 conduction velocity 55 ropinirole 55 psychiatric diagnoses 55 hyperglycaemia 55 nasal allergy symptoms 55 genital arousal 55 composite endpoint 55 hemoglobin A1c HbA1c 55 salmeterol fluticasone 55 serum vitamin D 55 lumbar disk herniation 55 cerebral infarction 55 dose dependently 55 plasma lipids 55 events AEs 55 dyssynchrony 55 hypoperfusion 55 intravascular hemolysis 55 adiponectin levels 55 buspirone 55 serum phosphate levels 55 APTIVUS r 55 oral prednisolone 55 postdischarge 55 subscale 55 cortical atrophy 55 ejaculatory function 55 lopinavir r arm 54 anhedonia 54 Comorbid 54 paresthesia 54 generalized estimating 54 aromatase inhibitor therapy 54 urine albumin 54 pulmonary exacerbations 54 Heritability 54 urinary cortisol 54 CIBIC plus 54 cardiometabolic risk 54 psychomotor agitation 54 airflow obstruction 54 spirometric 54 inhaled budesonide 54 Symptom Score 54 ALT flares 54 potassium sparing diuretics 54 fasting blood glucose 54 Insulin sensitivity 54 cognitive impairment 54 escitalopram Lexapro 54 morphometric vertebral fractures 54 venlafaxine Effexor 54 tertile 54 dysmenorrhoea 54 neurocognitive deficits 54 MIRAPEX 54 thyrotropin 54 ACR# [002] 54 Stroke Scale 54 tirofiban 54 Sleep disordered breathing 54 Baseline characteristics 54 acute gout flares 54 postoperative 54 subtrochanteric 54 ROZEREM 54 ULORIC 54 neurologic abnormalities 54 shorter telomere length 54 steroid dexamethasone 54 psychostimulants 54 QTcF 54 glomerular filtration rate 54 gout flare 54 Endothelial dysfunction 54 osmolality 54 quetiapine risperidone 54 urinary albumin excretion 54 urinary frequency 54 vesicoureteral reflux 54 zonisamide SR 54 neuropsychological assessment 54 citalopram Celexa 54 tonsillar hypertrophy 54 EEG abnormalities 54 hypoxemia 54 QT interval prolongation 54 proteinuria 54 hyperphenylalaninemia HPA due 54 Apidra ® 54 atrophic gastritis 54 procalcitonin 54 T1DM 54 zopiclone 54 antiarrhythmic drug 54 Poisson regression 54 blood Phe 54 Non inferiority 54 glycemia 54 depression suicidal ideation 54 tricyclic antidepressants 54 clinicopathological features 54 ACh 54 colorectal adenomas 54 certolizumab 54 recurrent ischemia 54 octreotide LAR 54 APOE genotype 54 habitual snoring 54 mIU L 54 atopic eczema 54 severe hypoglycemia 54 postprandial insulin 54 anticholinergic effects 54 thyroid hormone levels 54 extrapyramidal disorder 54 ALSFRS R 54 cardio respiratory fitness 54 highest tertile 54 arterial thickening 54 puerperal psychosis 54 Oswestry Disability Index 54 histological subtype 54 clobazam 54 atheroma volume 54 serum lipid levels 54 CrCl 54 anxiety irritability 54 perimenopausal women 54 mg kg dose 54 inotropic 54 COPD exacerbations 54 guanfacine 54 pressor response 54 hyperammonemia 54 calculated creatinine clearance 54 hyperprolactinemia 54 hypomania 54 LV ejection fraction 54 myopathy rhabdomyolysis 54 safinamide 54 laxation 54 nephrotoxicity 54 SGOT 54 Histologic 54 definite stent thrombosis 54 neurological abnormalities